Safety analysis of inactivated COVID-19 vaccines in people over 18 years of age in two cites in Anhui Province

LI Tao; TANG Jihai; HOU Lijuan; XUAN Kun; MAO Leijing; XU Haiyang; YAN Jianqiang; REN Zhongjie; WANG Binbing

doi:10.16462/j.cnki.zhjbkz.2024.11.011

Volume 28 Issue 11

Nov. 2024

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2024 > 28(11): 1308-1315

LI Tao, TANG Jihai, HOU Lijuan, XUAN Kun, MAO Leijing, XU Haiyang, YAN Jianqiang, REN Zhongjie, WANG Binbing. Safety analysis of inactivated COVID-19 vaccines in people over 18 years of age in two cites in Anhui Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(11): 1308-1315. doi: 10.16462/j.cnki.zhjbkz.2024.11.011

Citation:

LI Tao, TANG Jihai, HOU Lijuan, XUAN Kun, MAO Leijing, XU Haiyang, YAN Jianqiang, REN Zhongjie, WANG Binbing. Safety analysis of inactivated COVID-19 vaccines in people over 18 years of age in two cites in Anhui Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(11): 1308-1315. doi: 10.16462/j.cnki.zhjbkz.2024.11.011

Citation:

LI Tao, TANG Jihai, HOU Lijuan, XUAN Kun, MAO Leijing, XU Haiyang, YAN Jianqiang, REN Zhongjie, WANG Binbing. Safety analysis of inactivated COVID-19 vaccines in people over 18 years of age in two cites in Anhui Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(11): 1308-1315. doi: 10.16462/j.cnki.zhjbkz.2024.11.011

PDF( 860 KB)

Safety analysis of inactivated COVID-19 vaccines in people over 18 years of age in two cites in Anhui Province

doi: 10.16462/j.cnki.zhjbkz.2024.11.011

1.
Vaccine Clinical Evaluation Center, Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China
2.
Department of Immunoprophylaxis, Hefei Center for Disease Control and Prevention, Hefei 230091, China
3.
Department of Immunoprophylaxis, Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China
4.
Department of Immunoprophylaxis, Fuyang Center for Disease Control and Prevention, Fuyang 236000, China
5.
Department of Central office, Taihe Center for Disease Control and Prevention, Fuyang 236600, China
6.
Department of Immunoprophylaxis, Qiaocheng Center for Disease Control and Prevention, Bozhou 236800, China

Funds:

Health Research Program of Anhui AHWJ2023A20369

Anhui Provincial Center for Disease Control and Prevention (Anhui Institute of Public Health) Youth Research Program JKQN20230203

More Information

Corresponding author: WANG Binbing, E-mail: 250267563@qq.com
Received Date: 2024-01-22
Rev Recd Date: 2024-08-15

Available Online: 2024-12-23

Publish Date: 2024-11-10

Abstract

Abstract

Objective To evaluate the real-world safety of large-scale vaccination of inactivated novel coronavirus vaccine (inactivated vaccine) for adults aged among ≥18-year-old adults in two cities in Anhui Province. Methods An open-label study was conducted, with informed consent obtained. From June 2021 to June 2022, we recruited individuals aged ≥18 years from Taihe County, Fuyang City, and Qiaocheng District, Bozhou City, Anhui Province, for large-scale inactivated vaccine administration. The subjects were divided into healthy group and chronic underlying disease (referred to as underlying disease) group, and the incidence and severity of adverse reactions after each dose of vaccine were evaluated in the two groups. Results (1) A total of 12 257 subjects over 18 years old were included in this study, including 9 984 healthy subjects and 2 273 subjects with underlying diseases, and 11 874 subjects completed two doses of inactivated vaccine, with a full vaccination rate of 96.88%, and the top three underlying diseases were hypertension (68.28%), diabetes mellitus (18.43%), and cerebral infarction(8.32%). (2) The overall incidence of adverse reaction was 0.42% (51/12 257), all adverse reaction occurred within 28 days, the incidence of adverse reaction in the underlying disease group and the healthy group were 0.40% and 0.42%, respectively, with no statistically significant difference was observed (χ² =0.028, P=0.868). (3) Except for induration/swelling, there was no significant difference in adverse reaction between the healthy group and the underlying disease group (all P>0.05). The severity was mainly grade 1 (45 cases), and the incidence of grade 1 adverse reaction was 0.37%, there was no significant difference in the incidence of grade 1 and grade 2 adverse reaction between the two groups (all P>0.05). (4) The adverse reaction of the first dose and the second dose in the healthy group and the underlying disease group were mainly grade 1, and there was no significant difference in the grade of adverse reaction between the two doses (all P>0.05). Conclusions Adults over the age of 18 who receive the inactivated vaccine against the novel coronavirus have a good safety profile for different ages, different health conditions, and different doses.
- People over 18 years of age,
- People with chronic underlying medical conditions,
- Inactivated 2019-nCoV vaccine,
- Adverse reaction,
- Safety

FullText(HTML)

References(17)

References

[1]	Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor [J]. Cell, 2020, 181(2): 271-280. e8. DOI: 10.1016/j.cell.2020.02.052.
[2]	World Health Organization. WHO coronavirus (COVID-19) dashboard [EB/OL]. (2023-12-24) [2023-12-24]. https://covid19.who.int/.
[3]	廖聪慧, 王子晨, 邓强, 等. COVID-19疫苗上市后安全性及有效性的研究进展[J]. 暨南大学学报(自然科学与医学版), 2021, 42(5): 547-556. DOI: 10.11778/j.Jdxb.2021.05.011. Liao CH, Wang ZC, Deng Q, et al. Research progress on the safety and efficacy of COVID-19 vaccine after marketing [J]. Journal of Jinan University(Natural Science and Medical Science), 2021, 42(5): 547-556. DOI: 10.11778/j.Jdxb.2021.05.011.
[4]	黄勇, 李军宏, 宋渝丹, 等. 特殊健康状态人群新型冠状病毒疫苗接种有效性和安全性的真实世界研究进展[J]. 中国疫苗和免疫, 2022, 28(6): 720-729. DOI: 10.19914/j.CJVI.2022134. Huang Y, Li JH, Song YD, et al. Advances in real-world studies of the effectiveness and safety of coronavirus disease 2019 (COVID-19) vaccination in people with medical conditions [J]. Chinese Journal of Vaccines and Immunization, 2022, 28(6): 720-729. DOI: 10.19914/j.CJVI.2022134.CJVI.2022134.
[5]	国家药品监督管理局. 国家药监局关于发布预防用疫苗临床试验不良事件分级标准指导原则的通告(2019年第102号) [EB/OL]. (2019-12-31) [2023-12-28]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20191231111901460.html.
[6]	World Health Organization. COVID-19 vaccine tracker and landscape [EB/OL]. (2023-03-30) [2023-12-28]. https://www.who.int/teams/blueprint/covid-19/covid-19-vaccine-tracker-and-landscape.
[7]	孟彤彤, 孔庆福, 王富珍, 等. 新型冠状病毒灭活疫苗研究进展[J]. 中国疫苗和免疫, 2020, 26(5): 590-596. DOI: 10.19914/j.cjvi.2020.05.023. Meng TT, Kong QF, Wang FZ, et al. Progress on the research and development of inactivated novel coronavirus vaccines. [J]. Chinese Journal of Vaccines and Immunization, 2020, 26(5): 590-596. DOI: 10.19914/j.cjvi.2020.05.023.
[8]	Yang HT, Li Z, Zhang RZ, et al. Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac^Ⓡ) among population aged 3years and older in a large-scale use: a multi-center open-label study in China [J]. Vaccine, 2023, 41(7): 1354-1361. DOI: 10.1016/j.vaccine.2023.01.020.
[9]	Wan EYF, Wang Y, Chui CSL, et al. Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong : a modified self-controlled case series [J]. Lancet Healthy Longev, 2022, 3(7): e491-e500. DOI: 10.1016/S2666-7568(22)00125-8.
[10]	Han BH, Song YF, Li CG, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial [J]. Lancet Infect Dis, 2021, 21(12): 1645-1653. DOI: 10.1016/S1473-3099(21)00319-4.
[11]	穆秋玥, 冯添, 黄飞, 等. 3岁及以上人群新型冠状病毒灭活疫苗接种反应临床观察分析[J]. 中华流行病学杂志, 2023, 44(11): 1738-1743. DOI: 10.3760/cma.j.cn112338-20230328-00189. Mu QY, Feng T, Huang F, et al. Clinical observation on adverse reaction after vaccination of inactivated 2019-nCoV vaccine in population aged 3 years and above [J]. Chin J Epidemiol, 2023, 44(11): 1738-1743. DOI: 10.3760/cma.j.cn112338-20230328-00189.
[12]	杨中楠, 赵韵芽, 李璐, 等. 新型冠状病毒灭活疫苗(Vero细胞)大规模紧急使用安全性评价[J]. 中华流行病学杂志, 2021, 42(6): 977-982. DOI: 10.3760/cma.j.cn112338-20210325-00249. Yang ZN, Zhao YY, Li L, et al. Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use [J]. Chin J Epidemiol, 2021, 42(6): 977-982. DOI: 10.3760/cma.j.cn112338-20210325-00249.
[13]	朱立炜, 陈国杰, 姜凌, 等. 合肥市新型冠状病毒灭活疫苗(Vero细胞)紧急接种期间安全性[J]. 中华疾病控制杂志, 2021, 25(7): 802-805. DOI: 10.16462/j.cnki.zhjbkz.2021.07.012. Zhu LW, Chen GJ, Jiang L, et al. Safety analysis of inactivated SARS-CoV-2 vaccine (Vero cells) during emergency vaccination in Hefei [J]. Chin J Dis Control Prev, 2021, 25(7): 802-805. DOI: 10.16462/j.cnki.zhjbkz.2021.07.012.
[14]	国家卫生健康委员会. 新冠病毒疫苗接种技术指南(第一版) [J]. 传染病信息, 2021, 34(2): 97-98. DOI: 10.3969/j.issn.1007-8134.2021.02.001. National Health Commission. Technical guidelines for coronavirus vaccination (1st edition) [J]. Infect Dis Info, 2021, 34(2): 97-98. DOI: 10.3969/j.issn.1007-8134.2021.02.001.
[15]	Zhang YT, Chen HP, Lyu J, et al. Evaluation of immunogenicity and safety of vero cell-derived inactivated COVID-19 vaccine in older patients with hypertension and diabetes mellitus [J]. Vaccines, 2022, 10(7): 1020. DOI: 10.3390/vaccines10071020.
[16]	Ye XX, Ma TT, Blais JE, et al. Association between BNT162b2 or CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with cardiovascular disease [J]. Cardiovasc Res, 2022, 118(10): 2329-2338. DOI: 10.1093/cvr/cvac068.
[17]	Wang JT, Hou ZY, Liu JX, et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study [J]. J Hepatol, 2021, 75(2): 439-441. DOI: 10.1016/j.jhep.2021.04.026.